Health Force nets €4.2M to deploy its AI agents across Europe

Health Force has pulled in €4.2 million in seed funding to push its hospital AI agents beyond Italy. LUMO Labs led the round, with Target Global and Calm/Storm Ventures back again, alongside Step Venture and Next Tier Ventures.

The pitch is blunt: hospital software is a mess, so don’t make hospitals rebuild it. In Italy’s largest private hospital groups, Health Force says its agents can process three out of four insurance claims from start to finish without human help. The rest get handed back to staff with clear instructions on what needs attention. That’s a neat wedge into one of healthcare’s least glamorous problems, and it’s also the one that usually wastes the most time.

Fadi Haddad, Health Force’s co-founder and CEO, built the company after seeing how often hospitals and labs were stuck with systems that didn’t talk to each other. He had worked in Dubai, Singapore and Mexico City before moving to Vienna, where he later led business development at Medicus.ai. The company was founded in Vienna in 2022 with Juan Sebastián Suárez Valencia, a doctor and data engineer who previously served as Chief Data Officer at Teladoc France.

Health Force’s first hospitals came through Deloitte in Italy, including Humanitas Research Hospital and Ospedale Galeazzi of Gruppo San Donato. Those relationships turned into deeper partnerships, with the company jointly managing more than 200,000 patient cases a year. It later brought the platform to ULS Coimbra in Portugal for government quality reporting, not insurance work.

The company is betting that hospitals want agents that sit on top of old systems, not another layer of software theatre. Health Force’s engineers build the agents on site, and the company charges per agent delivered. It now has eight employees and plans to double that to sixteen by the end of the year, with hiring spread across Germany, Italy, Spain and France. Haddad also says the new money will help launch new agents, including one for clinical trial operations, while the company expands into Germany, France and Spain.